CR20170249A - Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas - Google Patents

Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas

Info

Publication number
CR20170249A
CR20170249A CR20170249A CR20170249A CR20170249A CR 20170249 A CR20170249 A CR 20170249A CR 20170249 A CR20170249 A CR 20170249A CR 20170249 A CR20170249 A CR 20170249A CR 20170249 A CR20170249 A CR 20170249A
Authority
CR
Costa Rica
Prior art keywords
solid state
forms
pirrolidinones
fusioned
heteroaromatic
Prior art date
Application number
CR20170249A
Other languages
English (en)
Inventor
Christopher Matthews
Kentaro Yaji
Chunrong Ma
Tomonori Ichibakase
Hajime Motoyoshi
Rongliang Chen
Colin O´Bryan
Naoki Yoshikawa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170249(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20170249A publication Critical patent/CR20170249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen entidades químicas que son inhibidores de la tirosina quinasa del bazo (SYK), a saber, entidades químicas que comprenden 6-((1R,2S)-2-aminociclohexilamino)-7-fluoro-4-(1-metil-1H-pirazol-4-il)-1H-pirrolo[3,4-c]piridina-3(2H)-ona y determinadas formas de estado sólido de este. También se describen métodos para usar las entidades químicas para tratar trastornos como el cáncer.
CR20170249A 2014-12-18 2015-12-17 Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas CR20170249A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16
PCT/IB2015/002489 WO2016097862A2 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Publications (1)

Publication Number Publication Date
CR20170249A true CR20170249A (es) 2017-09-25

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170249A CR20170249A (es) 2014-12-18 2015-12-17 Formas en estado sólido de pirrolidinonas heteroaromáticas fusionadas

Country Status (29)

Country Link
US (3) US10676473B2 (es)
EP (2) EP3233857B1 (es)
JP (3) JP6778195B2 (es)
KR (1) KR102037502B1 (es)
CN (1) CN107108609B (es)
AU (1) AU2015365580B2 (es)
BR (1) BR112017013149B1 (es)
CA (1) CA2970864C (es)
CL (1) CL2017001561A1 (es)
CO (1) CO2017005910A2 (es)
CR (1) CR20170249A (es)
DK (1) DK3233857T3 (es)
DO (1) DOP2017000130A (es)
EA (1) EA032291B1 (es)
EC (1) ECSP17038100A (es)
ES (1) ES2788454T3 (es)
GE (1) GEP20197050B (es)
HK (1) HK1243406A1 (es)
IL (1) IL252941B (es)
MX (1) MX2017007162A (es)
NZ (1) NZ732371A (es)
PE (1) PE20171179A1 (es)
PH (1) PH12017501123A1 (es)
PL (1) PL3233857T3 (es)
SG (1) SG11201701911QA (es)
TN (1) TN2017000080A1 (es)
UA (1) UA120632C2 (es)
WO (1) WO2016097862A2 (es)
ZA (1) ZA201701800B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013149B1 (pt) * 2014-12-18 2022-10-11 Takeda Pharmaceutical Company Limited Composto, composição farmacêutica e uso dos mesmos
WO2018013239A1 (en) * 2016-07-13 2018-01-18 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
BR112020007679A2 (pt) 2017-10-19 2020-10-20 Bayer Animal Health Gmbh uso de pirrolidonas heteroaromáticas fundidas para tratamento e prevenção de doenças em animais.
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
SG11202106210QA (en) 2018-12-14 2021-07-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Salt of syk inhibitor and crystalline form thereof
AU2020218154A1 (en) 2019-02-07 2021-08-05 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
JP2022552496A (ja) 2019-10-10 2022-12-16 ヤンセン バイオテツク，インコーポレーテツド ビアリールジヒドロオロト酸デヒドロゲナーゼ阻害剤
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
CN115698005B (zh) * 2020-12-18 2024-02-06 山东轩竹医药科技有限公司 稠环类AhR抑制剂
PE20240588A1 (es) 2021-05-11 2024-03-21 Janssen Pharmaceutica Nv Terapias de combinacion
JP2024518497A (ja) 2021-05-11 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 併用療法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070872A1 (en) * 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
ES2545616T3 (es) 2009-12-23 2015-09-14 Takeda Pharmaceutical Company Limited Pirrolidinonas heteroaromáticas condensadas como inhibidores de SYK
EP2723739B1 (en) * 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
WO2016048982A2 (en) * 2014-09-24 2016-03-31 Millennium Pharmaceuticals, Inc. COMBINATION TREATMENT WITH PI3Kα INHIBITORS AND TAXANES
BR112017013149B1 (pt) * 2014-12-18 2022-10-11 Takeda Pharmaceutical Company Limited Composto, composição farmacêutica e uso dos mesmos

Also Published As

Publication number Publication date
EA032291B1 (ru) 2019-05-31
CA2970864C (en) 2020-04-14
BR112017013149A2 (pt) 2018-04-10
BR112017013149B1 (pt) 2022-10-11
EP3233857B1 (en) 2020-03-11
CO2017005910A2 (es) 2017-10-20
CL2017001561A1 (es) 2018-01-12
US20230348461A1 (en) 2023-11-02
EP3677582A1 (en) 2020-07-08
EP3233857A2 (en) 2017-10-25
ES2788454T3 (es) 2020-10-21
DOP2017000130A (es) 2017-07-15
ECSP17038100A (es) 2017-12-01
CA2970864A1 (en) 2016-06-23
EA201791369A1 (ru) 2017-10-31
KR20170095374A (ko) 2017-08-22
MX2017007162A (es) 2017-08-28
AU2015365580B2 (en) 2020-04-02
AU2015365580A1 (en) 2017-07-06
JP2022017477A (ja) 2022-01-25
DK3233857T3 (da) 2020-04-27
UA120632C2 (uk) 2020-01-10
CN107108609A (zh) 2017-08-29
US10676473B2 (en) 2020-06-09
JP2020143081A (ja) 2020-09-10
WO2016097862A2 (en) 2016-06-23
IL252941A0 (en) 2017-08-31
GEP20197050B (en) 2019-12-10
US11352355B2 (en) 2022-06-07
JP6974534B2 (ja) 2021-12-01
KR102037502B1 (ko) 2019-10-28
PE20171179A1 (es) 2017-08-22
SG11201701911QA (en) 2017-04-27
HK1243406A1 (zh) 2018-07-13
WO2016097862A3 (en) 2016-08-11
NZ732371A (en) 2023-04-28
PH12017501123A1 (en) 2017-11-27
ZA201701800B (en) 2020-05-27
JP6778195B2 (ja) 2020-10-28
US20160176869A1 (en) 2016-06-23
EP3677582B1 (en) 2023-01-25
TN2017000080A1 (en) 2018-07-04
JP2017537969A (ja) 2017-12-21
US20200339573A1 (en) 2020-10-29
IL252941B (en) 2020-11-30
PL3233857T3 (pl) 2020-07-27
CN107108609B (zh) 2020-02-18

Similar Documents

Publication Publication Date Title
DOP2017000130A (es) Formas en estado solido de pirrolidinonas heteroaromaticas fusionadas
CO2017012947A2 (es) Inhibidores de tirosina-cinasas
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
SG10201807952PA (en) Jak1 inhibitors for the treatment of myelodysplastic syndromes
CL2018000596A1 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
EA201791133A1 (ru) Ингибиторы erk
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
AR101905A1 (es) Compuestos bicíclicos
EA201990523A1 (ru) НОВЫЕ СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Jak1 И ИХ ПРИМЕНЕНИЕ
DOP2018000201A (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2019005538A2 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017000586A2 (es) Formulación en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2017017119A (es) Formulacion de alta concentracion.
ECSP18000097A (es) Inhibidores de tirosina-cinasas